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Abstract
Objective To describe 20-year risk factor trajectories according to initial weight/health status and investigate the extent to
which baseline differences explain greater mortality among metabolically healthy obese (MHO) individuals than healthy
non-obese individuals.
Methods The sample comprised 6529 participants in the Whitehall II study who were measured serially between 1991–1994
and 2012–2013. Baseline weight (non-obese or obese; body mass index (BMI) ≥30 kg/m2) and health status (healthy or
unhealthy; two or more of hypertension, low high-density lipoprotein cholesterol (HDL-C), high triglycerides, high glucose,
and high homeostatic model assessment of insulin resistance (HOMA-IR)) were deﬁned. The relationships of baseline
weight/health status with 20-year trajectories summarizing ~25,000 observations of systolic and diastolic blood pressures,
HDL-C, triglycerides, glucose, and HOMA-IR were investigated using multilevel models. Relationships of baseline weight/
health status with all-cause mortality up until July 2015 were investigated using Cox proportional hazards regression.
Results Trajectories tended to be consistently worse for the MHO group compared to the healthy non-obese group (e.g.,
glucose by 0.21 (95% CI 0.09, 0.33; p < 0.001) mmol/L at 20-years of follow-up). Consequently, the MHO group had a
greater risk of mortality (hazard ratio 2.11 (1.24, 3.58; p= 0.006)) when the referent group comprised a random sample of
healthy non-obese individuals. This estimate, however, attenuated (1.34 (0.85, 2.13; p= 0.209)) when the referent group
was matched to the MHO group on baseline risk factors.
Conclusions Worse baseline risk factors may explain any difference in mortality risk between obese and non-obese groups
both labelled as healthy, further challenging the concept of MHO.
Introduction
Obesity is a major public health problem because of its
adverse consequences for long-term health and well-being
[1]. Clearly, however, not all obese individuals have the
same cardio-metabolic disease risk factor (e.g., blood
pressure and fasting glucose levels) proﬁles. The concept
that someone can be obese yet metabolically healthy, most
commonly called “metabolically healthy obesity (MHO)”,
has been highly controversial and widely debated [2, 3]. In
particular, two main types of epidemiological studies have
questioned whether or not MHO is truly a benign condition,
relative to metabolically healthy non-obese (MHNO). The
ﬁrst has investigated the progression of the MHO phenotype
over time, demonstrating that this group tends to develop
risk factors and transition to being unhealthy more fre-
quently than their non-obese counterparts [4–11]. Hamer
et al. [10] for example, demonstrated that, over 8 years of
follow-up in the English Longitudinal Study of Ageing,
45% of MHO participants transitioned to an unhealthy state
compared to 17% of MHNO participants [10]. The second
type of study has investigated disease prognosis or mor-
tality, demonstrating a ranking of risk according to both
weight and health status [12–20]. Lassale et al. [17] for
example, have recently reported hazard ratios for incident
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coronary heart disease, among ~18,000 European adults, of
1.28 (95% conﬁdence interval (CI) 1.03, 1.58) for MHO,
2.15 (1.79, 2.57) for metabolically unhealthy non-obese
(MUNO), and 2.54 (2.21, 2.92) for metabolically unhealthy
obesity (MUO), compared to a MHNO referent group [17].
Existing studies can therefore be summarised as providing
evidence that MHO is an intermediate state before the
development of cardio-metabolic abnormalities and, as
such, is related to increased disease and mortality risk.
A notable limitation of this literature is that all deﬁnitions
of MHO, most of which are based on blood pressure, high-
density lipoprotein cholesterol (HDL-C), triglycerides, and
plasma glucose, require continuous variables to be dichot-
omised (e.g., blood pressures to hypertension status). This
process often results in systematic differences in baseline
descriptive statistics among healthy or unhealthy indivi-
duals, according to weight status [4–18]. For example, the
Lassale et al. publication reported baseline levels of tri-
glycerides of 1.13 (1.10, 1.15) mmol/L in the MHNO group
and 1.22 (1.16, 1.27) in the MHO group [17]. These
inherent differences appear to be relatively small, but we do
not know how they change over follow-up, because no
study has described trajectories of continuous risk factors
over time according to baseline weight/health status. Such
trajectories would help understand why so-called MHO
individuals often transition to being unhealthy. Moreover,
previous studies have largely failed to consider the extent to
which inherent baseline differences might explain the
observed greater disease and mortality rates of obese com-
pared to non-obese individuals, who are all apparently
healthy. Evidence that both groups have the same mortality
risk when they are matched on baseline cardio-metabolic
disease risk factors would further challenge the concept of
MHO.
Using longitudinal data from the Whitehall II study, we
aimed to describe 20-year risk factor trajectories according
to initial weight/health status and investigate the extent to
which baseline differences might explain the expected
greater mortality of MHO compared to MHNO individuals.
Subjects and methods
Study sample
The Whitehall II study was established to explore the
relationship between socio-economic position, stress and
cardiovascular disease [21]. A cohort of 10,308 (6895 men;
3413 women) civil servants aged 35–55 years, working in
London, United Kingdom (UK) for the government, parti-
cipated in the baseline examination in 1985–1988 (response
74%). A combination of clinical and questionnaire data
from ﬁve repeated assessments (1991–1994, 1997–1999,
2002–2004, 2007–2009, and 2012–2013) over approxi-
mately two decades of follow-up were used in the present
paper. The 1991–1994 assessment was the ﬁrst to cover a
large range of biological measurements, including fasting
glucose, and was used as baseline in this analysis. The
University College London research ethics committee
granted ethical approval for each phase of data collection.
Participants provided written informed consent.
Starting with the 8815 cohort members who were still
participating in the study at baseline in 1991/1994, 1769
were excluded because of missing clinical data necessary to
deﬁne weight/health status at baseline, a further 50 because
their body mass index (BMI) at baseline was classiﬁed as
thin (i.e., <18.5 kg/m2), 457 because of missing baseline
covariate data, and 10 because they did not have a single
measurement of waist circumference across the ﬁve
assessments. The resulting sample comprised 6529 (4604
men; 1925 women) individuals, representing 71% of the
eligible cohort (i.e., N= 8815) and 63% of the total cohort
(i.e., N= 10,308).
Data
Clinical measurements
At each assessment, weight, height, and waist cir-
cumference (at the widest point) were measured by a trained
nurse according to standardized protocols, systolic blood
pressure (SBP) and diastolic blood pressure (DBP) were
assessed, and fasting blood samples were taken for bio-
chemical analysis of HDL-C, triglycerides, glucose, and
insulin levels, as previously described [5, 6, 22, 16, 21].
BMI was calculated as weight (kg)/height (m)2 and
homeostatic model assessment of insulin resistance
(HOMA-IR) as fasting glucose (mmol/L) × fasting insulin
(mmol/L)/22.5.
In total, there were 24,903 observations of BMI, 24,318
of waist circumference, 25,608 of SBP, 25,607 of DBP,
24,736 of HDL-C, 25,317 of triglycerides, 25,282 of fasting
glucose, and 23,805 of HOMA-IR. For each of these out-
comes, ~70% of the sample had four or ﬁve observations
and ~65% of the sample was followed-up for more than
17.5 years.
Covariates
Covariates at baseline were assessed via a questionnaire and
coded as follows. Age in decimal years (centred about the
mean), sex (female vs male), and ethnicity (non-white vs
white) were recorded in addition to socio-economic position
based on occupational role (clerical/support, administrative,
vs professional/executive). The following health behaviours
were also assessed: frequency of alcohol consumption
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(daily, weekly or monthly, vs never or special occasions),
smoking status (current, ex, vs never), and frequency of
mild and moderate exercise (1–3 times/month or seldom,
1–2 times/week, vs 3 times/week or more). The General
Health Questionnaire (GHQ-30) was administered to cap-
ture psychological distress and was coded as 10–30, 2–9, vs
0–1 after inspecting the distribution to create three reason-
ably sized categories [23]. Finally, diet was assessed via
questions on the frequency of consumption of 10 fruits and
18 vegetables, bread (white, brown, and wholemeal), and
milk (whole, semi-skimmed, skimmed, and others). Fruit
and vegetable consumption were deﬁned as healthy if they
reported eating any item once a day or more, unhealthy if
they did not eat any item at least 2–4 times a week, and
moderately healthy for everything in-between. Bread con-
sumption was deﬁned as healthy if they reported eating
brown bread or wholemeal bread more frequently than
white bread, unhealthy if they ate white bread most fre-
quently, and moderately healthy for everything else. Milk
consumption was deﬁned as healthy if they did not use any
milk or used skimmed or other types of milk, unhealthy if
they used whole milk, and moderately healthy if they used
semi-skimmed milk. A slightly modiﬁed version of a
composite dietary pattern score, used in previous Whitehall
II study publications, was then created [24]. Individuals
were deﬁned as healthy if they were healthy on all sub-
scales (i.e., fruit and vegetable, bread, and milk) with the
allowance of being moderately healthy on one sub-scale,
unhealthy if they were unhealthy on all sub-scales with the
allowance of being moderately healthy on one sub-scale,
and everyone else was classiﬁed as moderately healthy.
At each assessment, use of hypertension medication
(diuretics, beta-blockers, ACE inhibitors, calcium channel
blockers, and other antihypertensives), diabetes medication
(insulin and oral antidiabetic drugs), and cardiovascular
disease medication (antihypertensives, nitrates, antiplatelets,
and lipid-lowering drugs) medication were reported (yes vs
no).
Mortality records
Individual participant data were linked to death records
from the National Health Service (NHS) Central Register,
using NHS identiﬁcation numbers, up until July 2015. Six
participants were missing these data and were excluded
from analyses of all-cause mortality.
Statistical analyses
Weight status at baseline was deﬁned as non-obese
(18.5–29.9 kg/m2) or obese (≥30.0 kg/m2). On the basis of
independent criteria [25], and as in previous Whitehall II
publications [5, 6], health status at baseline was deﬁned as
healthy if participants had zero or one of the following ﬁve
cardio-metabolic disease risk factors and unhealthy if they
had two or more: blood pressure ≥130/85 mmHg or use of
hypertension medication, HDL-C <1.03 mmol/L for men
and <1.29 mmol/L for women, triglycerides ≥1.7 mmol/L,
fasting plasma glucose ≥5.6 mmol/L or use of diabetes
medication, and HOMA-IR >3.17 (90th percentile in the
sample). Individuals were then categorised as being
MHNO, MHO, MUNO, or MUO at baseline.
Descriptive statistics for baseline variables were pro-
duced stratiﬁed according to weight/health status, and
between-group differences (MHO vs MHNO and MUO vs
MUNO) were tested using χ2-tests for categorical variables
and t-tests for continuous variables.
Trajectory modelling
Trajectories were modelled in a multilevel general linear
regression framework (measurement occasion at level one
and individuals at level two) [26, 27], incorporating sys-
tematic differences in the sample-average trajectory
according to baseline weight/health status and adjustment
for covariates.
A separate model was built for each of the eight out-
comes (i.e., serial BMI, waist circumference, SBP, DBP,
HDL-C, triglycerides, glucose, and HOMA-IR). HDL-C,
triglycerides, glucose, and HOMA-IR were log transformed
due to skewed distributions, but all presented results have
been back-transformed to the original scales. The time scale
was decimal years of follow-up, modelled as a quadratic
polynomial function to allow nonlinear trajectories.
Exploratory analyses revealed that more complex functions,
including fractional polynomials and restricted cubic
splines, did not result in better ﬁtting models or noticeably
different sample-average trajectories. The constant and
quadratic polynomial terms (i.e., time and time2) were
allowed to have random effects at level two, with an
unstructured variance-covariance matrix.
In all instances, the baseline weight/health status expo-
sure was included as a main effect and as an interaction with
the quadratic polynomial terms, thereby allowing the
sample-average trajectory to be truly different for each
group. Adjustment was made for sex, ethnicity, baseline
covariates (age, alcohol, smoking, mild and moderate
exercise, occupational grade, GHQ, and diet) and medica-
tion at each assessment (hypertension medication for SBP
and DBP, cardiovascular disease medication for HDL-C
and triglycerides, and diabetes medication for glucose and
HOMA-IR).
The resulting covariate-adjusted trajectories, according to
weight/health status at baseline, were plotted for each out-
come separately. The models were also used to estimate
mean (95% CI) values and contrast differences between
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Table 1 Description of study sample at baseline, according to weight/health status
MHNO
(N= 4371)
MHO
(N= 272)
P-value MUNO
(N= 1487)
MUO
(N= 399)
P-value
Sex <0.001 <0.001
Male N (%) 3006 (69) 106 (39) 1256 (84) 236 (59)
Female N (%) 1365 (31) 166 (61) 231 (16) 163 (41)
Ethnicity <0.001 0.668
White N (%) 4044 (93) 229 (84) 1300 (87) 352 (88)
Non-white N (%) 327 (7) 43 (16) 187 (13) 47 (12)
Age (years) Mean (SD) 49.7 (6.0) 50.5 (5.8) 0.039 51.2 (6.1) 51.0 (6.0) 0.504
BMI (kg/m2) Mean (SD) 24.2 (2.5) 32.5 (2.6) <0.001 25.9 (2.2) 33.6 (3.6) <0.001
WC (cm) Mean (SD) 82.8 (9.7) 98.5
(10.5)
<0.001 90.3 (8.2) 105.3
(9.6)
<0.001
SBP (mmHg) Mean (SD) 117.7 (12.0) 122.4
(12.8)
<0.001 127.9 (14.5) 131.1
(13.2)
<0.001
DBP (mmHg) Mean (SD) 77.8 (8.4) 81.6 (8.9) <0.001 84.8 (9.3) 87.1 (9.1) <0.001
HDL-C (mmol/L) Median
(IQR)
1.47 (1.24,
1.74)
1.42
(1.24,
1.64)
0.046 1.07 (0.92,
1.33)
1.12
(0.94,
1.34)
0.629
Triglycerides (mmol/
L)
Median
(IQR)
1.02 (0.77,
1.37)
1.17
(0.95,
1.53)
<0.001 2.04 (1.59,
2.70)
2.05
(1.52,
2.82)
0.457
Glucose (mmol/L) Median
(IQR)
5.10 (4.90,
5.40)
5.10
(4.80,
5.30)
0.087 5.50 (5.20,
5.80)
5.60
(5.20,
6.00)
0.020
HOMA-IR Median
(IQR)
1.03 (0.66,
1.53)
1.69
(1.19,
2.29)
<0.001 1.91 (1.22,
3.12)
3.44
(2.34,
4.85)
<0.001
Alcohol <0.001 <0.001
Never or special
occasions
N (%) 631 (14) 73 (27) 229 (15) 106 (27)
Weekly or monthly N (%) 2220 (51) 119 (44) 722 (49) 185 (46)
Daily N (%) 1520 (35) 80 (29) 536 (36) 108 (27)
Smoking 0.783 0.060
Never N (%) 2143 (49) 128 (47) 664 (45) 152 (38)
Ex N (%) 1646 (38) 108 (40) 604 (41) 184 (46)
Current N (%) 582 (13) 36 (13) 219 (15) 63 (16)
Mild exercise <0.001 <0.001
Three times/week or
more
N (%) 2977 (68) 164 (60) 970 (65) 217 (54)
1–2 times/week N (%) 1101 (25) 73 (27) 390 (26) 122 (31)
1–3 times/month or
seldom
N (%) 293 (7) 35 (13) 127 (9) 60 (15)
Moderate exercise <0.001 <0.001
Three times/week or
more
N (%) 714 (16) 32 (12) 215 (15) 32 (8)
1–2 times/week N (%) 1990 (46) 94 (34) 712 (48) 159 (40)
1–3 times/month or
seldom
N (%) 1667 (38) 146 (54) 560 (38) 208 (52)
GHQ 0.729 0.005
0–1 N (%) 2657 (61) 169 (62) 983 (66) 230 (58)
2–9 N (%) 1234 (28) 71 (26) 384 (26) 124 (31)
10–30 N (%) 480 (11) 32 (12) 120 (8) 45 (11)
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groups (MHO vs MHNO and MUO vs MUNO) at baseline
and at 20 years of follow-up.
Survival analysis
To illustrate how even baseline differences in cardio-
metabolic disease risk factors may explain differences in
subsequent mortality between MHO and MHNO groups,
survival analysis was applied to three different samples. The
ﬁrst “full sample” comprised all MHO and MHNO indivi-
duals, the second “random sample” comprised the 270
MHO individuals (from the full sample) plus 270 randomly
selected MHNO individuals, and the third “matched sam-
ple” comprised the 270 MHO individuals plus 270 MHNO
individuals who were matched based on SBP and DBP and
log-transformed HDL-C, triglycerides, glucose, and
HOMA-IR at baseline. Propensity score matching was
implemented using logistic regression without replacement,
so that the matched group did not include the same indi-
vidual more than once. Matching was based on the best
propensity score for each MHNO individual and not any
other criteria (e.g., SBP within 2 mmHg etc.). To assess the
quality of the matching, differences in cardio-metabolic
disease risk factors at baseline between the MHNO and
MHO groups were estimated within each sample using
general linear regression models. HDL-C, triglycerides,
glucose, and HOMA-IR were log-transformed due to
skewed distributions; regression estimates were expo-
nentiated and can be interpreted as ratios of geometric
means.
For each sample, a Cox proportional hazards regression
model was built to test the association of weight/health
status (MHO vs MHNO) with all-cause mortality. Age at
death was recorded and decimal years were the time scale
for follow-up. For participants with no record of an event,
the data were censored at July 2015. Adjustment was made
for sex, ethnicity, and baseline covariates (age, alcohol,
smoking, mild and moderate exercise, occupational grade,
GHQ, and diet). After ﬁtting each model, the proportional
hazards assumption was examined using log–log plots and
tested using Schoenfeld residuals (all p-values >0.3, indi-
cating no violation).
All procedures were performed in Stata 15 (StataCorp
LP, College Station, TX, USA). The command runmlwin
was used for the multilevel models [28].
Code availability
The statistical code for the analyses in this paper is available
upon request from the corresponding author.
Results
Table 1 shows descriptive statistics of the study sample at
baseline, according to weight/health status. Approximately
90% of the sample was non-obese and 75% of these indi-
viduals were healthy. Conversely, among the 10% of the
sample that was obese only 40% were healthy. Despite both
the MHNO and MHO groups being labelled as healthy,
average levels of all cardio-metabolic disease risk factors
(except for glucose) were worse in the MHO group (e.g.,
SBP 122.4 vs 117.7 mmHg; HOMA-IR 1.69 vs 1.03).
Similarly, average levels of most cardio-metabolic disease
risk factors were worse in the MUO group compared to the
MUNO group.
Table 1 (continued)
MHNO
(N= 4371)
MHO
(N= 272)
P-value MUNO
(N= 1487)
MUO
(N= 399)
P-value
Grade <0.001 <0.001
Professional or
executive
N (%) 1975 (45) 134 (49) 697 (47) 173 (43)
Administrative N (%) 1731 (40) 69 (25) 582 (39) 115 (29)
Clerical or support N (%) 665 (15) 69 (25) 208 (14) 111 (28)
Diet 0.816 0.321
Healthy N (%) 1299 (30) 82 (30) 374 (25) 115 (29)
Moderately healthy N (%) 2516 (58) 159 (58) 858 (58) 221 (55)
Unhealthy N (%) 556 (13) 31 (11) 255 (17) 63 (16)
P-values are from χ2-tests for categorical variables and t-tests for continuous variables (HDL-C, triglycerides, glucose, and HOMA-IR were log-
transformed due to skewed distributions)
BMI body mass index, DBP diastolic blood pressure, GHQ general health questionnaire, HDL-C high-density lipoprotein cholesterol, HOMA-IR
homeostatic model assessment of insulin resistance, MHNO metabolically healthy non-obese, MHO metabolically healthy obese, MUNO
metabolically unhealthy non-obese, MUO metabolically unhealthy obese, SBP systolic blood pressure, WC waist circumference
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Trajectories
Overall ﬁts of the multilevel trajectory models were deter-
mined to be good according the residual standard devia-
tions, a measure of average error on the original scale used
for modelling (e.g., BMI 1.1 kg/m2 and DBP 6.5 mmHg).
Further, diagnostic plots of the level-one random effects
indicated comparable ﬁt across the four weight/health
groups and that the trajectories were not systematically too
high or low across time (data not shown).
Figure 1 shows the estimated covariate-adjusted trajec-
tories for each of the outcomes, according to weight/health
status at baseline. The y-axis for HDL-C is reversed so that
higher trajectories indicate worse levels for all outcomes.
For BMI and WC (Panels A & B), trajectories were con-
sistently higher for (1) the MUO group compared to the
MHO group and (2) the MUNO group compared to the
MHNO group. For the cardio-metabolic disease risk factors
(Panels C–H), trajectories tended to be higher for the MHO
group compared to the MHNO group; these differences had
p-values <0.05 at baseline and at 20 years of follow-up,
with the exceptions of glucose at baseline and SBP at 20
years of follow-up (Table 2). Further, cardio-metabolic
disease risk factor trajectories tended to be higher for the
MUO group compared to the MUNO group, although after
20 years of follow-up these differences were less apparent
for SBP, DBP, and HDL-C (Table 3).
All-cause mortality
Differences in baseline BMI, waist circumference, and
cardio-metabolic disease risk factors between MHNO and
MHO groups are presented in Table 4 for the full sample,
the random sample, and the matched sample. In agreement
with the previous results, in the full sample, all risk factors
except for glucose were worse in the MHO group compared
to the MHNO group. Estimated differences were compar-
able between the full sample and the random sample. For
example, SBP was 4.6 (95% CI 3.1, 6.1) mmHg higher
among MHO individuals (than MHNO individuals) in the
full sample, compared to 4.8 (2.6, 6.9) mmHg higher among
MHO individuals in the random sample. In the matched
sample, however, estimated differences between MHNO
and MHO groups in all cardio-metabolic disease risk factors
were attenuated to the null (e.g., 0.7 (−1.4, 2.8) for SBP),
thereby demonstrating that the propensity score matching
had served its purpose in creating a referent MHNO group
that differed from the MHO group only in BMI and WC.
A total of 517 deaths, among the 4638 MHNO or MHO
individuals, were observed over a median follow-up of 22.2
years (Table 5). In covariate-adjusted Cox proportional
hazards models, the MHO group had a greater risk of
mortality than the MHNO group in both the full sample
(Hazard Ratio 1.57 (95% CI 1.15, 2.15)) and the random
sample (2.11 (1.24, 3.58)). In the matched sample, however,
there was less evidence of an association between MHO and
all-cause mortality (1.34 (0.85, 2.13)).
Discussion
The key ﬁnding of the present paper is that after accounting
for baseline differences in cardio-metabolic disease risk
factors, by matching the referent MHNO group to the MHO
group on the risk factors used to deﬁne health status, the
difference in mortality risk between the two groups was
attenuated. As such, we provide evidence that documented
associations of MHO with disease or mortality risk might be
viewed as a statistical artifact that results from crudely
dichotomizing continuous variables to deﬁne weight/health
status. This ﬁnding does not mean that obesity is not
deleterious when the cardio-metabolic disease risk factors
we studied are at the same levels as those found in non-
obese individuals, because our mortality analysis in the
matched sample still revealed some residual risk associated
with obesity (hazard ratio 1.34). This suggests that genuine
healthy obese individuals are rare.
Much of the MHO literature has focused on prognosis,
and numerous systematic reviews and meta-analyses have
reported that MHO is associated with increased risk for
various diseases (e.g., type 2 diabetes, cardiovascular
events, chronic kidney disease, and depression) and mor-
tality, compared to a healthy non-obese referent group [29–
34]. Despite this strong evidence that MHO is not a benign
condition, studies are still frequently published on this
topic. For example, a recent analysis among 3.5 million
adults found that MHO (compared to MHNO) was asso-
ciated with a higher risk of developing coronary heart dis-
ease (Hazard Ratio 1.49 (95% CI 1.45, 1.54)),
cerebrovascular disease (1.07 (1.04, 1.11)), and heart failure
(1.96 (1.86, 2.06) over a mean follow-up of 5.4 years [13].
While many of these studies present baseline differences in
cardio-metabolic disease risk factors between these two
groups, which manifest from dichotomizing continuous
variables, few discuss the impact of these baseline differ-
ences on the reported relationships.
To illustrate the fact that applying binary cutoffs to
deﬁne weight/health status induces differences in cardio-
metabolic disease risk factors between MHO vs MHNO
groups (and between MUO vs MUNO groups) we also
present 20-year trajectories. For HDL-C and triglycerides,
higher average values among MHO than MHNO indivi-
duals remained remarkably similar in magnitude across
follow-up, thereby suggesting that accounting for baseline
differences (as in our mortality analyses) is approximately
the same as accounting for cumulative differences over
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Fig. 1 Trajectories of risk factors over 20 years of follow-up according to weight/health status at baseline, estimated using multilevel models.
The multilevel models were adjusted for sex, ethnicity, baseline covariates (age, alcohol, smoking, mild and moderate exercise, occupational grade,
GHQ, and diet), and medication at each assessment (for SBP, DBP, HDL-C, triglycerides, glucose, and HOMA-IR outcomes). MHNO N = 4371,
MHO N = 272, MUNO N = 1487, MUO N = 399. BMI body mass index, DBP diastolic blood pressure, GHQ general health questionnaire, HDL-
C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, MHNO metabolically healthy non-obese,
MHO metabolically healthy obese, MUNO metabolically unhealthy non-obese, MUO metabolically unhealthy obese, SBP systolic blood pressure,
WC waist circumference
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time. The differences for SBP and DBP reduced marginally
over time, but those for glucose and HOMA-IR increased
(e.g., from ~0.0 mmol/L at baseline to 0.2 mmol/L at 20-
years for glucose). These ﬁndings are in agreement with
previous Whitehall II study analyses showing that, relative
to MHNO, the incidence of MHO individuals developing
insulin resistance (incidence ratio 3.78 (95% CI 2.38, 5.99))
or high blood glucose (2.27 (1.43, 3.61)) over 20-years is
higher than that for hypertension (1.35 (1.03, 1.77)) [5]. It
appears that impairment of the glucose-insulin regulatory
system might be the main factor driving transition to an
unhealthy state, which would explain why the meta-
analysed association of MHO with incident type 2 dia-
betes (relative risk ~4.0) is stronger than that for cardio-
vascular disease (relative risk ~1.2) [29, 32].
Importantly, our results do not mean that a person cannot
be obese and have no complications. Key principles of
normal variation mean that two obese individuals, even with
exactly the same BMI, can (and most likely do) have dif-
ferent levels of cardio-metabolic disease risk factors. The
idea that some people demonstrate some level of “resilience
to obesity” is statistically plausible. And experimental
studies in animal models [35, 36], in addition observational
studies in humans [37], have started to reveal possible
biological mechanisms (e.g., a genetic variant in humans
near ISR1 has been shown to be related to both increased
percentage body fat and a favourable metabolic proﬁle [38])
beyond the obvious (e.g., high BMI due to high fat-free
mass). The problem is that MHO is a crude way of cap-
turing heterogeneity in health among individuals with the
same BMI level. For this reason, the concept of MHO may
have limited clinically utility. In a meta-analysis of nearly
150,000 participants from 14 cohort studies, Lotta et al., for
example, found that binary deﬁnitions of metabolic health
only had satisfactory sensitivity (0.81 (95% CI 0.76, 0.86))
and low speciﬁcity (0.42 (0.35, 0.49) for predicting incident
type 2 diabetes in obese individuals [33]. Despite these
limitations, a large part of the ﬁeld has not moved on from
asking whether or not people can be obese yet healthy. In
particular, we think that more research is needed on (1) the
joint distributions of BMI and cardio-metabolic disease risk
factors and (2) the life course exposures that might modify
the relationship of BMI with incident disease or mortality.
Such investigation would help us better understand the
Table 2 Estimated values of risk
factors in MHNO and MHO
groups from multilevel
trajectory models
MHNO (N= 4371) MHO (N= 272) MHO–MHNO
Mean (95% CI) Mean (95% CI) Mean (95% CI) P-value
Baseline
BMI (kg/m2) 23.9 (23.6, 24.2) 32.1 (31.7, 32.5) 8.2 (7.9, 8.5) <0.001
WC (cm) 84.3 (83.4, 85.1) 103.0 (101.7, 104.2) 18.7 (17.7, 19.7) <0.001
SBP (mmHg) 119.6 (118.3, 120.9) 125.0 (122.9, 127.1) 5.4 (3.7, 7.1) <0.001
DBP (mmHg) 79.2 (78.4, 80.1) 83.7 (82.4, 85.1) 4.5 (3.3, 5.7) <0.001
HDL-C (mmol/L) 1.33 (1.30, 1.36) 1.22 (1.18, 1.26) −0.11 (−0.15, −0.08) <0.001
Triglycerides (mmol/L) 1.01 (0.97, 1.06) 1.22 (1.14, 1.30) 0.20 (0.14, 0.27) <0.001
Glucose (mmol/L) 5.09 (5.04, 5.14) 5.08 (5.00, 5.16) −0.01 (−0.08, 0.06) 0.806
HOMA-IR 0.99 (0.93, 1.04) 1.55 (1.41, 1.68) 0.56 (0.44, 0.68) <0.001
20 years follow-up
BMI (kg/m2) 25.6 (25.3, 25.9) 34.2 (33.6, 34.8) 8.6 (8.1, 9.1) <0.001
WC (cm) 95.2 (94.3, 96.0) 114.3 (112.7, 115.9) 19.1 (17.7, 20.6) <0.001
SBP (mmHg) 131.4 (130.0, 132.8) 133.6 (130.9, 136.2) 2.2 (−0.2, 4.6) 0.078
DBP (mmHg) 73.2 (72.3, 74.1) 75.9 (74.2, 77.65) 2.7 (1.2, 4.2) <0.001
HDL-C (mmol/L) 1.51 (1.47, 1.54) 1.38 (1.32, 1.43) −0.13 (−0.18, −0.08) <0.001
Triglycerides (mmol/L) 1.02 (0.98, 1.07) 1.19 (1.11, 1.28) 0.17 (0.10, 0.24) <0.001
Glucose (mmol/L) 5.18 (5.13, 5.24) 5.40 (5.27, 5.52) 0.21 (0.09, 0.33) 0.001
HOMA-IR 1.48 (1.40, 1.57) 2.39 (2.13, 2.65) 0.91 (0.67, 1.14) <0.001
The multilevel models were adjusted for sex, ethnicity, baseline covariates (age, alcohol, smoking, mild and
moderate exercise, occupational grade, GHQ, and diet), and medication at each assessment (for SBP, DBP,
HDL-C, triglycerides, glucose, and HOMA-IR outcomes). The estimates correspond to the trajectories
shown in Fig. 1
BMI body mass index, DBP diastolic blood pressure, GHQ general health questionnaire, HDL-C high-
density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, MHNO
metabolically healthy non-obese, MHO metabolically healthy obese, MUNO metabolically unhealthy non-
obese, MUO metabolically unhealthy obese, SBP systolic blood pressure, WC waist circumference
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proportion and type of people who develop a high BMI
without any adverse consequences.
The main strength of the present article is the thorough
analysis of longitudinal data collected on a relatively large
sample over 20 years of follow-up to address a novel
research question. In terms of limitations, (1) the Whitehall
II study sample is not representative of the wider UK
population, although standard risk factor-cardiovascular
disease associations in Whitehall II are comparable to
those found in nationally representative studies [39], (2) we
only used one deﬁnition of MHO, which does not incor-
porate other measures/indicators of adiposity (e.g., waist
circumference), (3) the estimated relationships might be
subject to residual confounding, and (4) there were not
enough cases to investigate cause-speciﬁc mortality. While
these types of considerations are important when trying to
infer causality from observational data, we believe they are
less important for our given research aim to demonstrate
why other studies (which are subject to the same limita-
tions) ﬁnd what they ﬁnd. The results we present are a
demonstration of some of the possible consequences of
converting continuous variables to binary concepts, and
may be relevant to discussions on other related phenomena,
such as the “fat but ﬁt” paradigm [40].
Conclusion
This paper demonstrates how dichotomising continuous
variables results in different levels of cardio-metabolic
disease risk factors at baseline and over 20 years of follow-
up between MHO and MHNO individuals, despite both
groups having the same label of “healthy”, and to a lesser
extent between MUO and MUNO individuals. The greater
disease and mortality risk of MHO compared to MHNO
individuals, observed in large-scale epidemiological
studies, is likely largely explained by the more deleterious
risk factor trajectories (in the MHO group) that result
from crude stratiﬁcation. Future research needs to better
quantify heterogeneity in disease and mortality risk among
people with the same BMI, and investigate the character-
istics and life-course factors that explain why some people
develop a disease or die while other people with the same
BMI do not.
Table 3 Estimated values of risk
factors in MUNO and MUO
groups from multilevel
trajectory models
MUNO (N= 1487) MUO (N= 399) MUNO–MUO
Mean (95% CI) Mean (95% CI) Mean (95% CI) P-value
Baseline
BMI (kg/m2) 25.6 (25.3, 25.9) 33.1 (32.7, 33.5) 7.6 (7.3, 7.9) <0.001
WC (cm) 89.7 (88.8, 90.6) 107.2 (106.1, 108.3) 17.5 (16.6, 18.4) <0.001
SBP (mmHg) 129.5 (128.0, 130.9) 134.2 (132.3, 136.1) 4.7 (3.2, 6.3) <0.001
DBP (mmHg) 86.2 (85.3, 87.1) 89.4 (88.2, 90.7) 3.2 (2.2, 4.3) <0.001
HDL-C (mmol/L) 1.04 (1.01, 1.06) 1.01 (0.97, 1.04) −0.03 (−0.06, −0.005) 0.020
Triglycerides (mmol/L) 1.97 (1.88, 2.06) 2.01 (1.89, 2.13) 0.04 (−0.06, 0.14) 0.390
Glucose (mmol/L) 5.48 (5.42, 5.54) 5.63 (5.55, 5.72) 0.15 (0.08, 0.22) <0.001
HOMA-IR 1.80 (1.69, 1.91) 3.19 (2.93, 3.44) 1.39 (1.18, 1.60) <0.001
20 years follow-up
BMI (kg/m2) 27.0 (26.6, 27.3) 34.7 (34.2, 35.2) 7.7 (7.2, 8.2) <0.001
WC (cm) 98.9 (97.9, 99.9) 115.7 (114.3, 117.2) 16.8 (15.5, 18.2) <0.001
SBP (mmHg) 135.4 (133.8, 137.1) 136.1 (133.7, 138.5) 0.7 (−1.6, 2.9) 0.550
DBP (mmHg) 74.2 (73.1, 75.2) 75.2 (73.7, 76.7) 1.0 (−0.4, 2.4) 0.153
HDL-C (mmol/L) 1.23 (1.20, 1.26) 1.20 (1.16, 1.24) −0.03 (−0.07, 0.006) 0.095
Triglycerides (mmol/L) 1.40 (1.33, 1.47) 1.51 (1.41, 1.61) 0.11 (0.02, 0.19) 0.015
Glucose (mmol/L) 5.54 (5.46, 5.61) 5.83 (5.71, 5.95) 0.29 (0.17, 0.41) <0.001
HOMA-IR 2.44 (2.28, 2.60) 3.36 (3.02, 3.71) 0.92 (0.61, 1.23) <0.001
The multilevel models were adjusted for sex, ethnicity, baseline covariates (age, alcohol, smoking, mild and
moderate exercise, occupational grade, GHQ, and diet), and medication at each assessment (for SBP, DBP,
HDL-C, triglycerides, glucose, and HOMA-IR outcomes). The estimates correspond to the trajectories
shown in Fig. 1
BMI body mass index, DBP diastolic blood pressure, GHQ general health questionnaire, HDL-C high-
density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, MHNO
metabolically healthy non-obese, MHO metabolically healthy obese, MUNO metabolically unhealthy non-
obese, MUO metabolically unhealthy obese, SBP systolic blood pressure, WC waist circumference
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Table 5 Differences in all-cause mortality between MHNO and MHO
groups in the full sample, a 1:1 random sample, and a 1:1 matched
sample, estimated using cox proportional hazards models
N total N (%)
deaths
HR (95% CI) P-value
Full sample
MHNO 4368 472 (10.8) 1.0 (ref)
MHO 270 45 (16.7) 1.57 (1.15,
2.15)
0.005
1:1 random
sample
MHNO 270 25 (9.3) 1.0 (ref) 0.006
MHO 270 45 (16.7) 2.11 (1.24,
3.58)
1:1 matched
sample
MHNO 270 37 (13.7) 1.0 (ref)
MHO 270 45 (16.7) 1.34 (0.85,
2.13)
0.209
The “random sample” comprises the 270 MHO individuals (from the
full sample) plus 270 randomly selected MHNO individuals. The
“matched sample” comprises the 270 MHO individuals plus 270
MHNO individuals who were matched, using propensity score
matching, based on SBP, DBP, HDL-C, triglycerides, glucose, and
HOMA-IR. The cox proportional hazards models were adjusted for
sex, ethnicity, and baseline covariates (age, alcohol, smoking, mild
and moderate exercise, occupational grade, GHQ, and diet)
DBP diastolic blood pressure, GHQ general health questionnaire,
HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic
model assessment of insulin resistance, MHNO metabolically healthy
non-obese, MHO metabolically healthy obese, SBP systolic blood
pressure
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